1
|
Lima LG, Chammas R, Monteiro RQ, Moreira
ME and Barcinski MA: Tumor-derived microvesicles modulate the
establishment of metastatic melanoma in a
phosphatidylserine-dependent manner. Cancer Lett. 283:168–175.
2009. View Article : Google Scholar : PubMed/NCBI
|
2
|
Cocucci E, Racchetti G and Meldolesi J:
Shedding microvesicles: artefacts no more. Trends Cell Biol.
19:43–51. 2009. View Article : Google Scholar : PubMed/NCBI
|
3
|
Ghosh AK, Secreto CR, Knox TR, Ding W,
Mukhopadhyay D and Kay NE: Circulating microvesicles in B-cell
chronic lymphocytic leukemia can stimulate marrow stromal cells:
implications for disease progression. Blood. 115:1755–1764. 2010.
View Article : Google Scholar
|
4
|
Esquela-Kerscher A and Slack FJ: Oncomirs
- microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.
View Article : Google Scholar
|
5
|
Zhang Q, Pu R, Du Y, Han Y, Su T, Wang H
and Cao G: Non-coding RNAs in hepatitis B or C-associated
hepatocellular carcinoma: potential diagnostic and prognostic
markers and therapeutic targets. Cancer Lett. 321:1–12. 2012.
View Article : Google Scholar : PubMed/NCBI
|
6
|
Li D, Zhao Y, Liu C, et al: Analysis of
miR-195 and miR-497 expression, regulation and role in breast
cancer. Clin Cancer Res. 17:1722–1730. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Heneghan HM, Miller N, Lowery AJ, Sweeney
KJ, Newell J and Kerin MJ: Circulating microRNAs as novel minimally
invasive biomarkers for breast cancer. Ann Surg. 251:499–505. 2010.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Waters PS, McDermott AM, Wall D, et al:
Relationship between circulating and tissue microRNAs in a murine
model of breast cancer. PLoS One. 7:e504592012. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kutay H, Bai S, Datta J, et al:
Downregulation of miR-122 in the rodent and human hepatocellular
carcinomas. J Cell Biochem. 99:671–678. 2006. View Article : Google Scholar : PubMed/NCBI
|
10
|
Gramantieri L, Ferracin M, Fornari F, et
al: Cyclin G1 is a target of miR-122a, a microRNA frequently
down-regulated in human hepatocellular carcinoma. Cancer Res.
67:6092–6099. 2007. View Article : Google Scholar : PubMed/NCBI
|
11
|
Xu J, Wu C, Che X, et al: Circulating
microRNAs, miR-21, miR-122, and miR-223, in patients with
hepatocellular carcinoma or chronic hepatitis. Mol Carcinog.
50:136–142. 2011. View
Article : Google Scholar : PubMed/NCBI
|
12
|
Ji J, Yamashita T, Budhu A, et al:
Identification of microRNA-181 by genome-wide screening as a
critical player in EpCAM-positive hepatic cancer stem cells.
Hepatology. 50:472–480. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Zhan MX, Li Y, Hu BS, et al: Expression of
serum microRNAs (miR-222, miR-181, miR-216) in human hepatocellular
carcinoma and its clinical significance. Zhonghua Yi Xue Za Zhi.
93:1830–1832. 2013.(In Chinese).
|
14
|
Li QJ, Chau J, Ebert PJ, et al: miR-181a
is an intrinsic modulator of T cell sensitivity and selection.
Cell. 129:147–161. 2007. View Article : Google Scholar : PubMed/NCBI
|
15
|
Chen CZ, Li L, Lodish HF and Bartel DP:
MicroRNAs modulate hematopoietic lineage differentiation. Science.
303:83–86. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Liu Y, Zhao JJ, Wang CM, et al: Altered
expression profiles of microRNAs in a stable hepatitis B
virus-expressing cell line. Chin Med J (Engl). 122:10–14.
2009.PubMed/NCBI
|
17
|
Wald AI, Hoskins EE, Wells SI, Ferris RL
and Khan SA: Alteration of microRNA profiles in squamous cell
carcinoma of the head and neck cell lines by human papillomavirus.
Head Neck. 33:504–512. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu X, Wang T, Wakita T and Yang W:
Systematic identification of microRNA and messenger RNA profiles in
hepatitis C virus-infected human hepatoma cells. Virology.
398:57–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
19
|
El-Ekiaby, Hamdi N, Negm M, et al:
Repressed induction of interferon-related microRNAs miR-146a and
miR-155 in peripheral blood mononuclear cells infected with HCV
genotype 4. FEBS Open Bio. 2:179–186. 2012. View Article : Google Scholar : PubMed/NCBI
|
20
|
Li YP, Gottwein JM, Scheel TK, Jensen TB
and Bukh J: MicroRNA-122 antagonism against hepatitis C virus
genotypes 1–6 and reduced efficacy by host RNA insertion or
mutations in the HCV 5′ UTR. Proc Natl Acad Sci USA. 108:4991–4996.
2011.PubMed/NCBI
|
21
|
Chomczynski P and Sacchi N: Single-step
method of RNA isolation by acid guanidinium
thiocyanate-phenol-chloroform extraction. Anal Biochem.
162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
|
22
|
Hu Z, Chen X, Zhao Y, et al: Serum
microRNA signatures identified in a genome-wide serum microRNA
expression profiling predict survival of non-small-cell lung
cancer. J Clin Oncol. 28:1721–1726. 2010. View Article : Google Scholar : PubMed/NCBI
|
23
|
Köberle V, Waidmann O, Kronenberger B, et
al: Serum microRNA-122 kinetics in patients with chronic hepatitis
C virus infection during antiviral therapy. J Viral Hepat.
20:530–535. 2013.PubMed/NCBI
|
24
|
Su TH, Liu CH, Liu CJ, et al: Serum
microRNA-122 level correlates with virologic responses to pegylated
interferon therapy in chronic hepatitis C. Proc Natl Acad Sci USA.
110:7844–7849. 2013. View Article : Google Scholar : PubMed/NCBI
|
25
|
Sarasin-Filipowicz M, Krol J, Markiewicz
I, Heim MH and Filipowicz W: Decreased levels of microRNA miR-122
in individuals with hepatitis C responding poorly to interferon
therapy. Nat Med. 15:31–33. 2009. View Article : Google Scholar : PubMed/NCBI
|
26
|
Bala S, Tilahun Y, Taha O, Alao H, Kodys
K, Catalano D and Szabo G: Increased microRNA-155 expression in the
serum and peripheral monocytes in chronic HCV infection. J Transl
Med. 10:1512012. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhang Y, Wei W, Cheng N, Wang K, Li B,
Jiang X and Sun S: Hepatitis C virus-induced up-regulation of
microRNA-155 promotes hepatocarcinogenesis by activating Wnt
signaling. Hepatology. 56:1631–1640. 2012. View Article : Google Scholar : PubMed/NCBI
|